CorFlow Therapeutics AG
A prospective, multicenter, international single-arm, pivotal clinical study designed to validate the performance of the CoFI system in detecting MVO in STEMI subjects, as confirmed by CMRI. The study will be conducted in accordance with the Declaration of Helsinki, EN ISO 14155:2020, local and national regulations. Each study site will receive support from a sponsor-certified proctor during the learning curve to ensure consistent and accurate application of the CoFI system.
Microvascular obstruction (MVO) is a common complication that occurs after establishing coronary vessel patency by percutaneous coronary intervention (PCI) for the treatment of acute myocardial infarction (AMI). Despite the successful restoration of vessel patency through PCI, 50% to 70% of STEMI subjects experience MVO, which affects vessels in the myocardial microcirculation. MVO occurs most commonly in the setting of AMI because the prolonged ischemia leads to endothelial damage, myocyte oedema and micro-vascular dysfunction. Research has shown that MVO increases the risk of poor clinical…
Clinical: 1. Subject ≥18 years of age 2. Ability to provide written informed consent according to GCP and governing regulations 3. Diagnosis of acute anterior STEMI 4. First Medical Contact (FMC) to balloon time ≤ 6 hours. PPCI \& Angiographic 1\. Culprit lesion in the LAD 2. COFI ballon can be placed according to IFU 3. Required stent diameter ≥ 2.75 mm and ≤ 5mm 4. Required stent length ≥ 15 mm 5. Successful PPCI Procedure as documented by \<50% diameter residual angiographic stenosis within all treated culprit lesions with TIMI 2 or 3 flow and no presence of a post-intervention non-stente…
The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.